Welcome to our dedicated page for JNCE news (Ticker: JNCE), a resource for investors and traders seeking the latest updates and insights on JNCE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JNCE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JNCE's position in the market.
Jounce Therapeutics (NASDAQ: JNCE) announced its third-quarter 2020 results, reporting a net loss of $24.9 million, or $0.73 per share. The company initiated the Phase 2 SELECT trial for vopratelimab and established a license agreement with Gilead for JTX-1811, receiving $120 million in cash. Jounce's cash position decreased to $105.3 million by September 30, 2020, primarily due to operating expenses, with a projected annual cash burn of $80 million to $95 million. Upcoming milestones include starting a Phase 1 trial for JTX-8064 by year-end 2020.
Jounce Therapeutics (NASDAQ: JNCE) announced that the EMERGE Phase 2 trial of vopratelimab combined with ipilimumab will not proceed with further enrollment due to interim analysis findings indicating it will not meet specified continuation criteria. Conversely, the SELECT Phase 2 trial has commenced dosing its first patient, focusing on vopratelimab in combination with JTX-4014 for immunotherapy-naive NSCLC patients. While the EMERGE trial showed safety in the combination therapy, it highlighted a critical unmet need in the PD-(L)1 resistant population.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) will report its third quarter 2020 financial results and provide a corporate update on November 6, 2020, before market open. The management team will host a conference call at 8:00 a.m. ET, accessible via telephone and live webcast. Jounce focuses on developing cancer immunotherapies, with multiple programs ongoing. Key candidates include vopratelimab, currently in Phase 2 trials, and JTX-8064, a planned Phase 1 trial starting in Q4 2020. Jounce also licensed JTX-1811 to Gilead Sciences.
Jounce Therapeutics, a clinical-stage company focused on developing cancer immunotherapies, will participate in three investor conferences this September. The events include the Baird 2020 Global Healthcare Conference on September 9 at 12:50 p.m. ET, the Wells Fargo Virtual Healthcare Conference on September 10 at 3:20 p.m. ET, and the H.C. Wainwright 22nd Annual Healthcare Conference on September 14 at 3:00 p.m. ET. Webcast replays will be available for 30 days post-event on their website.
Gilead Sciences and Jounce Therapeutics entered a significant partnership, granting Gilead exclusive rights to develop and commercialize the JTX-1811 monoclonal antibody. This antibody targets immunosuppressive tumor-infiltrating T regulatory cells, aiming to enhance cancer treatment. Gilead will make an upfront payment of $85 million and a $35 million equity investment, with potential future payments up to $685 million based on milestones. Jounce retains development oversight until IND filing, anticipated in early 2021.
Jounce Therapeutics (NASDAQ: JNCE) reported its Q2 2020 financial results, ending with $127.2 million in cash and equivalents. The company completed enrollment for the Phase 2 EMERGE trial, focusing on non-small cell lung cancer, and is set for an interim efficacy analysis in early 2021. They aim to initiate the Phase 2 SELECT trial and Phase 1 trial for JTX-8064. Notably, net loss for Q2 was $28.0 million, with an EPS loss of $0.82, compared to $7.0 million loss in Q2 2019. Jounce anticipates a gross cash burn of $80-95 million for 2020.
Jounce Therapeutics (NASDAQ: JNCE) will report its second quarter 2020 financial results and provide a corporate update on August 7, 2020, before market open. The management team will host a live conference call and webcast at 8:00 a.m. ET. Investors can access the conference by dialing domestic (866) 916-3380 or international (210) 874-7772 using conference ID 3898328. Jounce is focused on developing novel cancer immunotherapies, with key programs including vopratelimab in Phase 2 trials and JTX-4014, a PD-1 inhibitor.
Jounce Therapeutics (NASDAQ: JNCE) presented new preclinical data for JTX-1811, an anti-CCR8 antibody, at the AACR Virtual Annual Meeting, showcasing its ability to selectively deplete immunosuppressive T-regulatory cells. JTX-1811 demonstrated synergy with PD-1 inhibitors in resistant tumor models. Additionally, vopratelimab's analysis revealed durable clinical responses linked to specific T cell populations. Jounce plans to file an Investigational New Drug application for JTX-1811 in early 2021. These developments enhance the company's scientific platform and bolster its commitment to cancer treatment advancements.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) will participate in a fireside chat at the Raymond James Human Health Innovation Conference on June 17, 2020, at 3:00 p.m. ET. This event will focus on the company's innovative cancer immunotherapies and predictive biomarkers. Interested parties can access a live webcast on Jounce's website under the 'Events and Presentations' section, with a replay available for 30 days post-event. Jounce continues to develop its clinical-stage programs, including vopratelimab and JTX-4014, aimed at enhancing cancer treatment.
Jounce Therapeutics (NASDAQ: JNCE) has announced its decision to conduct the 2020 Annual Meeting of Stockholders virtually due to COVID-19 concerns, prioritizing participant safety. The meeting is scheduled for June 26, 2020, at 9:00 a.m. ET, accessible via a live audio webcast. Only stockholders as of April 28, 2020, can vote, either in advance or online during the meeting. Jounce focuses on developing cancer immunotherapies, with notable projects including vopratelimab and JTX-4014, currently in clinical trials. More details can be found on the company’s website.
